
Date: 03-10-2025

**To,
The Deputy Manager
(Department of Corporate Services)
BSE Limited
P. J. Towers Dalal Street,
Fort, Mumbai- 400001**

Sub Intimation of Board Meeting pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: Scrip Code: 512600

Security Id: ASTALLTD

Respected Sir/ Madam,

With reference to the captioned subject, and pursuant to the Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we would like to inform you that a meeting of the Board of Directors of the Company is scheduled on Thursday, 9th October, 2025 at corporate office of the Company at House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032 to consider and approve the following:

- 1) To increase authorised share capital of the Company in accordance with Companies Act, 2013 and subject to any regulatory/ statutory approvals, as may be required and the approval of the shareholders of the Company;
- 2) To consider and if thought fit, approve the issuance of equity shares / convertible warrants of the Company on a preferential basis in accordance with the Companies Act, 2013 read with the rules notified thereunder, each as amended, and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and such other acts, rules and regulations, as may be applicable, subject to any regulatory/ statutory approvals, as may be required and the approval of the shareholders of the Company;
- 3) To discuss and take final decision on acquisition of 100 % equity shares of M/s Sriven Pharmachem India Private Limited ("SPIPL");
- 4) To adopt and approve the Draft Notice of Extra Ordinary General Meeting of the Company;
- 5) To fix the day, date, time and venue of Extra Ordinary General Meeting of the Company;
- 6) To appoint Scrutinizer for conducting E- voting process for Extra Ordinary General Meeting;
- 7) Any other Matter with the permission of the chair;

As intimated vide our letter dated 30th September, 2025 please note that, in terms of the “Code of Conduct for Regulating, Monitoring and Reporting of trading by Insiders” as adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window, for dealing in the Equity Shares of the Company by all Directors, Officers, Designated Persons and their immediate relatives, have already been closed from 1st October, 2025 till expiry of 48 hours after the declaration of the Unaudited Financial Results of the Company for the quarter ended 30th September, 2025.



Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com; Mob. No: 6302730973, Website: <https://astallabs.com/>

Accordingly, all Directors, Officers, Designated Persons and their immediate relatives have been informed not to trade in the securities of the Company during the aforesaid period of closure of Trading Window.

Thanking you,

Yours sincerely,

For Astal Laboratories Limited

Mahendra Kumar
(Company Secretary & Compliance officer)
Membership No.: A71224